Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Natacha Mauz
Observed names:
Mauz Natacha,
N. Mauz
Institution:
Centre Hospitalier Annecy Genevois
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Centre Hospitalier Universitaire de Grenoble,
Centre Hospitalier Annecy Genevois,
Translational Innovation in Medicine and Complexity,
Institut pour l'avancée des biosciences,
Université Grenoble Alpes
show all 7
ORCID:
0000-0002-3891-7354
Observed ORCID:
0000-0002-3891-7354
OpenAlex ID:
A5024466585
Perfusion magnetic resonance imaging: Comparison of semiologic characteristics in first-pass perfusion of brain tumors at 1.5 and 3 Tesla
2012
·
Natacha Mauz
, Alexandre Krainik
, et al.
·
Journal of Neuroradiology
·
23
Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate
2019
·
Johanna Zannoni
, Natacha Mauz
, et al.
·
Blood Advances
·
14
PDF
Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes
2018
·
Mathieu Meunier
, Charles Dussiau
, et al.
·
Oncotarget
·
12
PDF
Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group
2023
·
Zofia Gross
, Urbain Tauveron-Jalenques
, et al.
·
Blood
·
11
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
2023
·
Aurelie Cabannes-Hamy
, Lucien Courtois
, et al.
·
Blood
·
6
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry
2026
·
Maël Heiblig
, Zofia Gross
, et al.
·
Leukemia
·
4
PDF
Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
2024
·
Emmanuelle Tavernier
, Jérôme Cornillon
, et al.
·
Blood
·
3
PDF
Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
2024
·
Mael Heiblig
, Gaspar Aspas Requena
, et al.
·
Blood
·
3
Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
2024
·
Martin Carre
, Mathieu Meunier
, et al.
·
Blood
·
2
Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
2024
·
Adrien Contejean
, Pierre Chauvelot
, et al.
·
Blood
·
2
PDF
Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
2024
·
Nicolas Boissel
, Emilie Lemasle
, et al.
·
Blood
·
2
PDF
Rapid response system for critically ill patients with haematological malignancies: A pre‐ and post‐intervention study
2024
·
N. Mauz
, M. Bouisse
, et al.
·
European Journal Of Haematology
·
2
Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group
2026
·
Urbain Tauveron-Jalenques
, Gaspar Aspas Requena
, et al.
·
Bone Marrow Transplantation
·
1
PDF
Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study
2025
·
Gaspar Aspas Requena
, Pedro Chorao
, et al.
·
Blood
·
1
PDF
AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
2023
·
Maël Heiblig
, Emmanuelle Tavernier
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Interpretability of the Quantra viscoelastic test in patients with haematological malignancies presenting severe thrombocytopenia
2026
·
Adrien Contejean
, Florence Blanc-Jouvan
, et al.
·
Blood Coagulation & Fibrinolysis
Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
2024
·
Urbain Tauveron-Jalenques
, Zofia Gross
, et al.
·
Blood
POSTER: AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
2023
·
Maël Heiblig
, Emmanuelle Tavernier
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Tumor Microenvironment and Clonal Monocytes of Chronic Myelomonocytic Leukemia Induce a Procoagulant Climate within the Tumor Niche
2017
·
Natacha Mauz
, Mathieu Meunier
, et al.
·
Blood
Show more works
View as search
Works count:
20
Citation count:
91
H-index:
5
I10-index:
4
Year
Topic
Type